At 15, He Was Diagnosed with T-Lymphoblastic Lymphoma. His Father Kept Learning, Searching, and Standing Beside Him on the Road to Sustained Deep Remission

Summary: Fifteen-year-old Xiaohao had been enjoying high school life when a lump in his neck led to an unexpected diagnosis of T-lymphoblastic lymphoma. As treatment became more complex, his father began reading extensively, searching for a more standardized approach that could offer his son the best chance of long-term benefit. In 2025, Xiaohao came to the Department of Pediatric Hematology & Oncology at Beijing GoBroad Boren Hospital. Professor Yonghong Zhang's team conducted a comprehensive reassessment and carefully planned his subsequent treatment based on the disease characteristics, treatment response, and risk factors. After nearly a year of guideline-aligned, systematic treatment, Xiaohao achieved sustained deep remission and has now entered maintenance therapy. His father, whom other families came to call a 'research-minded parent,' shares what he learned along the way in the hope that their experience can offer practical reference and encouragement to other families facing adolescent hematologic cancers.

In January 2025, 15-year-old Xiaohao (pseudonym), from Jiangsu, was diagnosed with T-lymphoblastic lymphoma. After completing four initial cycles of chemotherapy at another hospital, his family traveled to Beijing in search of more standardized and precise follow-up treatment that could give him the best chance of long-term disease control. They came to the Department of Pediatric Hematology & Oncology at Beijing GoBroad Boren Hospital. Based on Xiaohao's disease features, Professor Yonghong Zhang's team developed an individualized treatment plan and managed every stage closely. After nearly a year of systematic treatment, Xiaohao achieved sustained deep remission and successfully transitioned to maintenance therapy. He is now moving steadily toward recovery.

Photo at Discharge

A Lump Appears in a 15-Year-Old's Neck - and Leads to an Unexpected Cancer Diagnosis

Just after the 2025 New Year holiday, we received a call from our son's high school. His teacher said she had felt a fairly large lump on Xiaohao's neck and suggested that we take him to a hospital as soon as possible. We did not dare delay. We took him to a local hospital immediately, where ultrasound and CT scans showed enlarged lymph nodes in his neck and in several other areas of his body. The doctor advised us to transfer him to a higher-level hospital for further evaluation.

We took Xiaohao to a provincial hospital right away. The days waiting for the pathology result felt endless; I barely slept, and every minute seemed to drag. Then the pathology report finally came back: T-lymphoblastic lymphoma, Stage II, Group A.

At 15, Xiaohao's life was only just beginning to unfold, yet suddenly he had been handed a challenge none of us had ever imagined. From the moment we received that report, the calm, ordinary life our family had known was completely changed.

Chemotherapy Starts to Work, but the Family Travels to Beijing for More Standardized Care

At the provincial hospital, Xiaohao quickly started chemotherapy. The first two cycles worked well, shrinking the mediastinal tumor by 65%. But we could not relax. T-LBL is an aggressive disease, long-term outcomes can vary, and relapse is always a concern. What worried us most was that Xiaohao had not been treated with a pediatric protocol; instead, he was receiving a modified adult regimen. That left us uncertain about whether the treatment was truly standardized for someone his age and what it might mean for his long-term outcome.

During that period, I began reading everything I could find about T-LBL: Chinese medical papers, English-language guidelines, clinical studies, patient forums - anything related to the disease. I went through the information carefully, trying to work out which direction might be most appropriate for my son. That was how I first learned about Professor Yonghong Zhang. She is a leading specialist in pediatric lymphoma in China and founded the China National Childhood Lymphoma Cooperative Group (CNCL). Her team has extensive clinical experience in standardized treatment and the management of difficult pediatric T-LBL cases.

My wife and I also learned a great deal from other families and from published clinical cases. We kept hearing that for T-LBL, families often sought specialist care in either Shanghai or Beijing. In the end, we decided to go to Beijing to see Professor Zhang's team. We felt that her expertise and clinical experience in T-LBL gave us the greatest confidence and made her team the one we most trusted with our son's care.

In April 2025, as soon as Xiaohao completed his fourth cycle of chemotherapy at the provincial hospital, we took him to Beijing and began the next stage of treatment.

Switching to a Pediatric Protocol: Precision Treatment for a Stronger Path to Long-Term Recovery

In May 2025, we brought Xiaohao to Beijing GoBroad Boren Hospital. The team promptly completed additional evaluations and invited Professor Chunju Zhou to review his recent outside PET/CT imaging. The review showed residual disease in the mediastinum but no evidence of progression. Because Xiaohao was an adolescent, Professor Zhang's team reassessed his stage using the International Pediatric Non-Hodgkin Lymphoma Staging System (IPNHSS). Given the bulky mediastinal disease, he was reclassified as Stage III, CNS2.

Continuing the modified adult regimen would have meant a lower likelihood of durable remission and a higher risk of relapse. After a comprehensive review, Professor Zhang's team quickly optimized the treatment strategy. They switched Xiaohao from the modified adult regimen to the CNCL-NHL-2017-LBL high-risk protocol, which is better suited to children and adolescents. Treatment restarted from the induction phase with VDLP chemotherapy, with bortezomib added to improve steroid sensitivity and strengthen the foundation for the stages that followed.

As I stayed beside my son and continued learning, I gradually came to understand how different pediatric lymphoma care can be from adult lymphoma treatment. Accurate staging, a standardized protocol, and a plan that reflects the physiology of children and adolescents can all have a direct impact on long-term outcomes and relapse risk.

Two weeks after starting induction chemotherapy, MRI showed that the residual mediastinal lesion had shrunk further, and there was no progression through discharge. That result made us even more confident that coming to Beijing had been the right decision. Taking into account the initially bulky disease, the possibility that residual tumor was still active when he arrived in Beijing, and several potentially adverse mutations identified on genetic testing, Professor Zhang's team ultimately chose a high-risk treatment protocol to maximize his chance of durable disease control.

Chemotherapy brought one challenge after another: bone marrow suppression, infections and fever, mouth ulcers, drug-induced liver injury, and coagulation abnormalities. Each episode was frightening for us as parents. Fortunately, Professor Zhang's team responded calmly and promptly every time, helping Xiaohao safely through one complication after another.

By early February 2026, after precise risk stratification and standardized treatment by the specialist team, Xiaohao had achieved sustained deep remission and smoothly entered the maintenance phase. On the day he was discharged, seeing how happy and excited he was made all the travel, worry, and difficult days feel worthwhile. Now, I simply look forward to staying beside him as he takes one steady step after another toward recovery.

Becoming a 'Research-Minded Parent': What One Father Learned Along the Way

Over the year I spent accompanying Xiaohao through treatment, I gradually changed from an anxious, overwhelmed parent into what other families jokingly called a 'research-minded parent.' That probably has something to do with my own work in data analysis. In my spare time, I also run an online account with more than 50,000 followers where I share analysis and observations. I am used to organizing information in a rational, structured way, so I approached the details of my son's treatment the same way. It helped make this complicated medical journey feel clearer and more manageable. I want to share some of the lessons I learned in the hope that our real experience can help other families facing similar uncertainty.

1. The Right Specialist Team Can Matter Even More Than the Name of the Hospital

Xiaohao's initial treatment at the provincial hospital produced a reasonable response, but I still insisted on bringing him to Beijing because I wanted a team with deep expertise in pediatric T-LBL. At Boren, Professor Zhang's team used precise risk stratification, individualized treatment, and tightly coordinated scheduling. Whenever Xiaohao's clinical condition and blood counts allowed, the next stage of treatment moved forward promptly, without unnecessary delay.

Through nationwide patient and parent groups, I met many families and heard about children whose treatment was interrupted or delayed before the disease had been adequately controlled. In some cases, treatment gaps can give tumor cells an opportunity to become resistant, which is heartbreaking. For an aggressive hematologic cancer such as T-LBL, timely and standardized treatment is critically important. An experienced team can make the right judgment at key moments. The team also uses molecular testing to refine disease classification, guide treatment choices, and assess risk, making treatment more evidence-based and more individualized.

2. Infection Is Never a Small Issue - Prevention Matters More Than Rescue

Before coming to Beijing, Xiaohao had two significant infections at the provincial hospital: influenza A and influenza B. The crowded ward environment made infection prevention particularly difficult. During chemotherapy-induced bone marrow suppression, a child's immune defenses can be extremely low. A serious infection can interrupt chemotherapy, worsen the overall condition, add financial burden, and in severe cases become life-threatening. From my perspective, reducing the risk of cross-infection is an important part of safely delivering intensive chemotherapy.

3. Nutrition Is the Foundation: Eating Well Helps the Body Get Through Treatment

During chemotherapy, Xiaohao often had poor appetite, nausea, bloating, and periods when he needed a low-fat diet. I spent a lot of time working out foods he might actually want to eat - for example, making braised chicken with minimally processed seasonings or a mild, non-spicy version of dishes he normally liked. I also found that plain sparkling water sometimes helped his bloating after medication. Ultimately, recovery requires adequate nutrition. White blood cell recovery and hematopoietic recovery both depend on sufficient protein and overall nutritional support. With the medical team's approval, and only when it would not interfere with treatment or add unnecessary liver or kidney burden, I also used appropriate nutritional supplements. These cannot replace medical treatment, but they may help address nutritional gaps when dietary intake is limited.

4. A Positive Mindset Is Not Just a Slogan - It Is Part of Getting Through Treatment

At the provincial hospital, most of the patients around Xiaohao were middle-aged or older adults, and the ward often felt quiet and heavy. After transferring to Boren, he was surrounded mostly by children and teenagers, and the atmosphere immediately felt more lively. The hospital also regularly organized activities such as birthday celebrations, craft sessions, and charity events. Xiaohao received several small gifts as well. He may no longer think of himself as a little child, but the happiness on his face whenever he received one was impossible to hide. A positive, hopeful state of mind may be invisible, but for us it clearly helped him get through one cycle of treatment after another.

Looking back on this past year, it was undeniably difficult, but it also changed the way our whole family sees life. We adjusted our diet and daily routines alongside Xiaohao, and we learned how to find a sense of certainty even when so much felt uncertain. As I gradually began sharing the things I had learned, I discovered that helping other people can also be a way of healing yourself.

There is still a long road ahead, but at least for now, sunlight has returned to our lives. Xiaohao is feeling better day by day, and our family is filled with renewed hope. We are deeply grateful to Professor Yonghong Zhang's team for their expertise and attentive care, and to every person who reached out to help us along the way. We also hope that our experience can offer even a small measure of reassurance and confidence to families who are still going through their own difficult season.